Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

被引：2

作者：

Poveda, Andres

Lheureux, Stephanie

Colombo, Nicoletta

Cibula, David

Lindemann, Kristina

Weberpals, Johanne I.

Bjurberg, Maria

Oaknin, Ana

Sikorska, Magdalena

Gonzalez Martin, Antonio

Madry, Radoslaw

Jesus Rubio, Maria

Ledermann, Jonathan A.

Davidson, Richard

Blakeley, Christopher

Bennett, James

Brown, Jessica

Skof, Erik

机构：

[1] Initia Oncol, Valencia, Spain

[2] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada

[3] IEO Ist Europeo Oncol, Milan, Italy

[4] Charles Univ Hosp, Fac Med 1, Prague, Czech Republic

[5] Oslo Univ Hosp, Oslo, Norway

[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[7] Lund Univ, Skane Univ Hosp, Lund, Sweden

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[9] Olsztyn Prov Specialist Hosp, Olsztyn, Poland

[10] Clin Univ Navarra, Madrid, Spain

[11] Lords Med Univ Karol Marcinkowski, Clin Hosp Transfigurat, Poznan, Poland

[12] Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain

[13] UCL, UCL Canc Inst, London, England

[14] UCL Hosp, London, England

[15] AstraZeneca, Cambridge, England

[16] Inst Oncol Ljubljana, Ljubljana, Slovenia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.5545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5545

引用

页数：4

共 50 条

[31] Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1-and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer
Penson, Richard
Valencia, Ricardo Villalobos
Colombo, Nicoletta
Leath, Charles
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo-Hyun
Madry, Radoslaw
Hernandez, Carlos
Mora, Paulo
Ryu, Sang-Young
Milenkova, Tsveta
Lowe, Elizabeth
Lukashchuk, Natalia
McNamara, John
Scambia, Giovanni
GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S20
[32] Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report
Skof, Erik
Stegel, Vida
Dragos, Vita Setrajcic
Blatnik, Ana
Gregoric, Brigita
Skerl, Petra
Klancar, Gasper
Klasinc, Anja Zagozen
Bombac, Alenka
Kraje, Mateja
Novakovic, Srdjan
GYNECOLOGIC ONCOLOGY, 2024, 190 : 104 - 112
[33] Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
Korach, J.
Freyer, G.
Banerjee, S.
Asher, R.
Cosin, J.
Oza, A. M.
Poveda, A. M.
Di Napoli, M.
Scott, C.
Lapresa, M.
Heitz, F.
Takehara, K.
Sonke, G. S.
Tjulandin, S.
Kim, J-W.
Hegg, R.
Vergote, I. B.
Turner, S.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2018, 29
[34] Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
Korach, Jacob
Turner, Simon
Milenkova, Tsveta
Alecu, Iulian
McMurtry, Emma
Bloomfield, Ralph
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[35] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J. Carl
Matulonis, Ursula
LANCET ONCOLOGY, 2014, 15 (08): : 852 - 861
[36] Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Matulonis, U. A.
Penson, R. T.
Domchek, S. M.
Kaufman, B.
Shapira-Frommer, R.
Audeh, M. W.
Kaye, S.
Molife, L. R.
Gelmon, K. A.
Robertson, J. D.
Mann, H.
Ho, T. W.
Coleman, R. L.
ANNALS OF ONCOLOGY, 2016, 27 (06) : 1013 - 1019
[37] Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses
Oza, A. M.
Cibula, D.
Oaknin Benzaquen, A.
Poole, C. J.
Mathijssen, R. H. J.
Sonke, G. S.
Mackay, H.
Lowe, E. S.
Read, J.
Friedlander, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S712 - S713
[38] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
Liu, Jihong
Yin, Rutie
Wu, Lingying
Zhu, Jianqing
Lou, Ge
Wu, Xiaohua
Zhou, Qi
Gao, Yunong
Kong, Beihua
Lu, Xin
Wang, Jing
Chen, Youguo
Cheng, Ying
Wang, Yueling
Lu, Weiguo
Li, Wei
Ma, Xin
Hsu, Kate
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
[39] Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
Cheng, Li-Jen
Wong, Grace
Chay, Wen-Yee
Ngeow, Joanne
Tan, Yongqiang
Soon, Swee Sung
Aziz, Mohamed Ismail Abdul
Pearce, Fiona
Ng, Kwong
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 441 - 448
[40] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
Friedlander, M.
Gebski, V.
Gibbs, E.
Bloomfield, R.
Hilpert, F.
Wenzel, L. B.
Joly, F.
Eek, D.
Rodrigues, M.
Clamp, A.
Penson, R.
Provencher, D.
Korach, J.
Huzarski, T.
Vidal, L.
Salutari, V.
Scott, C.
Nicoletto, M. O.
Tamura, K.
Pujade-Lauraine, E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941

← 1 2 3 4 5 →